Synthesis of a New Heterocyclic System: Pyrimidine Structural Analogues of Natural Integrastatins A, B

Semyon Y. Chikunov; Irina A. Pustolaikina; Yuriy V. Gatilov; Ivan V. Kulakov

doi:10.1055/a-2239-6657

Synlett, Inhaltsverzeichnis

Synlett 2024; 35(15): 1799-1806
DOI: 10.1055/a-2239-6657

letter

Synthesis of a New Heterocyclic System: Pyrimidine Structural Analogues of Natural Integrastatins A, B

Authors

Semyon Y. Chikunov

^aInstitute of Chemistry, Tyumen State University, 15a Perekopskaya St., Tyumen 625003, Russian Federation

^bLaboratory of Theory and Optimization of Chemical and Technological Processes, Tyumen State University, 15a Perekopskaya St., Tyumen, 625003, Russian Federation
Irina A. Pustolaikina

^cKaragandy University of the name of academician E.A. Buketov, Karaganda, 100024, Kazakhstan
Yuriy V. Gatilov

^dN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Science, 9 Akademika Lavrientieva Ave., Novosibirsk 630090, Russian Federation
Ivan V. Kulakov ∗

^aInstitute of Chemistry, Tyumen State University, 15a Perekopskaya St., Tyumen 625003, Russian Federation

Abstract

Alle Artikel dieser Rubrik

Abstract

In this paper for the first time, we report a simple one-step synthesis of 5-methyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-d]pyrimidine derivatives by acid-catalyzed cyclization reaction of various 4-methyl-5-acetyl pyrimidine derivatives with salicylic aldehyde. It was shown that 2-substituted 4-methyl-5-acetylpyrimidines successfully react to form a cyclization product. At the same time, 4-methyl-5-acetylpyrimidines with a substituent in the 6^th position do not enter into the cyclization reaction. This may be caused by the negative effect of substituents in the 6^th position, which hinder the free rotation of the acetyl group and prevent the formation of a stable pre-reaction complex. The structures of the obtained 5-methyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-d]pyrimidine derivatives were confirmed using ¹H NMR and ¹³C NMR spectroscopy, mass spectrometry, and X-ray diffraction analysis.

Key words

integrastatins - 4-methyl-5-acetyl derivatives of pyrimidine - salicylic aldehyde - intramolecular cyclization - epoxybenzo[7,8]oxocino[4,3-d]pyrimidines

Volltext

Referenzen

References and Notes
1 Lancet 2020; 396: 1703
2 Sullivan PS, Satcher Johnson A, Pembleton ES, Stephenson R, Justice AC, Althoff KN, Beyrer C. Lancet 2021; 397: 1095
3 Lancet 2023; 402: 585
4 Patil SB. Heliyon 2023; 9: e16773
5 Denel-Bobrowska M, Olejniczak AB. Eur. J. Med. Chem. 2022; 231: 114136
6 Popović-Djordjević J, Quispe C, Giordo R, Kostić A, Katanić Stanković JS, Valere P, Fokou T, Carbone K, Martorell M, Kumar M, Pintus G, Sharifi-Rad J, Docea AO, Calina D. Eur. J. Med. Chem. 2022; 233: 114217
7 Albratty M, Alhazmi HA. Arabian J. Chem. 2022; 15: 103846
8 Wang S, Yuan X.-H, Wang S.-Q, Zhao W, Chen X.-B, Yu B. Eur. J. Med. Chem. 2021; 214: 113218
9 Finger V, Kufa M, Soukup O, Castagnolo D, Roh J, Korabecny J. Eur. J. Med. Chem. 2023; 246: 114946
10 Kulakov IV, Stalinskaya AL, Chikunov SY, Gatilov YV. New J. Chem. 2021; 45: 3559
11 Oleshchuk AL, Karbainova AA, Krivoruchko TN, Shulgau ZT, Seilkhanov TM, Kulakov IV. Chem. Heterocycl. Compd. 2019; 55: 47
12 Singh SB, Zink DL, Quamina DS, Pelaez F, Teran A, Felock P, Hazuda DJ. Tetrahedron Lett. 2002; 43: 2351
13 El Amrani M, Lai D, Debbab A, Aly AH, Siems K, Seidel C, Schnekenburger M, Gaigneaux A, Diederich M, Feger D, Lin W, Proksch P. J. Nat. Prod. 2014; 77: 49
14 Foot JS, Giblin GM, Taylor RJ. Org. Lett. 2003; 5: 4441
15 Foot JS, Giblin GM, Whitwood AC, Taylor RJ. Org. Biomol. Chem. 2005; 3: 756
16 Ramana CV, Reddy CN, Gonnade RG. Chem. Commun. 2008; 3151
17 More AA, Ramana CV. Org. Lett. 2016; 18: 612
18 More AA, Ramana CV. Org. Lett. 2016; 18: 1458
19 Tadross PM, Bugga P, Stoltz BM. Org. Biomol. Chem. 2011; 9: 5354
20 Jeong JY, Sperry J, Brimble MA. J. Org. Chem. 2019; 84: 11935
21 Yamagiwa Y, Haruna N, Kawakami H, Matsumoto K. Bull. Chem. Soc. Jpn. 2020; 93: 1036
22 Stalinskaya AL, Chikunov SY, Pustolaikina IA, Kulakov IV. Russ. J. Gen. Chem. 2022; 92: 914
23 Stalinskaya AL, Chikunov SY, Pustolaikina IA, Gatilov YV, Kulakov IV. Synthesis 2024; 56: 329
24 Stalinskaya AL, Martynenko NV, Shulgau ZT, Shustov AV, Keyer VV, Kulakov IV. Molecules 2022; 27: 3701
25 Stalinskaya AL, Martynenko NV, Alkhimova LE, Dilbaryan DS, Vasilchenko AS, Dengis NA, Vlasenko VS, Kulakov IV. J. Mol. Struct. 2023; 1275: 134689
26 Danagulyan GG. Mkrtchyan A. D, Sahakyan LG. Chem. Heterocycl. Compd. 2005; 41: 262
27 Holmes B, Pennington W, Hanks T. Molecules 2002; 7: 447
28 Sayed HH, Moustafa AH, Yousif NM, Assy MG, Abd El-Halim MA. Phosphorus, Sulfur Silicon Relat. Elem. 2008; 183: 2318
29 El-Bahae S. Pharmazie 1990; 45: 6
30 Naydenova K, Muir KW, Wu LF, Zhang Z, Coscia F, Peet MJ, Castro-Hartmann P, Qian P, Sader K, Dent K, Kimanius D, Sutherland JD, Löwe J, Barford D, Russo C. J. Proc. Natl. Acad. Sci. U.S.A. 2021; 118: e2021946118
31 Kuroda DG, Bauman JD, Challa JR, Patel D, Troxler T, Das K, Arnold E, Hochstrasser RM. Nat. Chem. 2013; 5: 174
32 Das K, Bauman JD, Clark AD. J.r, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 1466
33 Kadam RU, Wilson IA. Proc. Natl. Acad. Sci. U.S.A. 2017; 114: 206
34 Harrus D, Ahmed-El-Sayed N, Simister PC, Miller S, Triconnet M, Hagedorn CH, Mahias K, Rey FA, Astier-Gin T, Bressanelli S. J. Biol. Chem. 2010; 285: 32906
35 https://www.rcsb.org/ (accessed January 29, 2024)
36 Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. J. Comput. Chem. 2009; 16: 2785
37 Trott O, Olson AJ. J. Comput. Chem. 2010; 31: 455
38 Discovery Studio 2015: Dassault Systemes BIOVIA, Discovery Studio Modelling E.
39 Synthesis of Compounds 2a–e: General Procedure In a round-bottom one-neck flask 10 mmol of initial pyrimidine, 15 mmol of salicylic aldehyde, and 15 mol% (80 mol% for initial pyrimidine 1e) of trifluoroacetic acid were placed. To the mixture was added 5 mL of isopropyl alcohol and boiled with a reflux condenser for 10 h. The obtained reaction mixture was diluted with 30 mL of dichloromethane and treated with 20% sodium hydroxide solution until complete removal of salicylic aldehyde from the mixture, determined by the absence of yellow coloring of the aqueous phase. The aqueous solutions were additionally extracted three times with 15 mL of dichloromethane. The combined organic phases were dried with anhydrous sodium sulfate and evaporated under reduced pressure. The crude product was purified chromatographically (silica gel, ethyl acetate/hexane, 1:3) or recrystallized from a suitable solvent.
40 5-Methyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-d]pyrimidine (2a) Сolorless crystals, 1.92 g, 80%, mp 186–188 °С (2-PrOH). ¹H NMR (500 MHz, CDCl₃): δ = 1.99 (s, 3 H, 5-CH₃), 3.06 (d, J = 17.8 Hz, 1 H, H-12a), 3.64 (dd, J = 17.8, 5.6 Hz, 1 H, H-12b), 5.43 (d, J = 5.6 Hz, 1 H, H-11), 6.76 (dd, J = 8.3, 1.1 Hz, 1 H, H-7), 6.91 (td, J = 7.5, 1.2 Hz, 1 H, H-9), 7.03 (dd, J = 7.7, 1.6 Hz, 1 H, Н-10), 7.12 (td, J = 8.5, 1.6 Hz, 1 H, Н-8), 8.80 (s, 1 H, H-4), 9.02 (s, 1 H, H-2) ppm. ¹³C NMR (CDCl₃, 126 MHz): δ = 162.8, 156.6, 153.5, 150.2, 130.9, 129.3, 125.6, 122.1, 121.7, 117.0, 95.0, 68.9 (CH), 38.8 (CH₂), 25.6 (CH₃) ppm. MS (EI): m/z (Irel, %) = [M⁺] 240.01 (29), 222.97 (100), 197.00 (12). HRMS: m/z calcd for [C₁₄H₁₂N₂O₂ ⁺]: 240.0899; found [M⁺]: 240.0894.
41 2,5-Dimethyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-d]pyrimidine (2b) Colorless crystals, 0.99 g, 39%, mp 146–148 °С (2-PrOH). ¹H NMR (500 MHz, CDCl₃): δ = 1.97 (s, 3 H, 5-CH₃), 2.67 (s, 3 H, 2-CH₃), 3.00 (d, J = 17.6 Hz, 1 H, H-12a), 3.59 (dd, J = 17.6, 5.6 Hz, 1 H, H-12b), 5.41 (d, J = 5.5 Hz, 1 H, H-11), 6.76 (dd, J = 8.3, 1.1 Hz, 1 H, H-7), 6.90 (td, J = 7.48, 1.15 Hz, 1 H, H-9), 7.03 (dd, J = 1.6, 7.7 Hz, 1 H, H-10), 7.12 (td, J = 8.6, 1.6 Hz, 1 H, H-8), 8.68 (s, 1 H, H-4) ppm. ¹³C NMR (CDCl₃, 126 MHz): δ = 167.6, 162.0, 154.2, 150.6, 129.2, 127.5, 125.7, 122.6, 121.5, 117.1, 95.5, 69.2 (CH), 39.0 (CH₂), 25.8 (CH3), 25.6 (CH₃) ppm. MS (EI): m/z (Irel, %) = [M⁺] 254.15 (100), 253.14 (35), 239.13 (20), 237.13 (20), 212.15 (13), 211.07 (75), 170.10 (13), 115.08 (16), 53.06 (13), 43.08 (40). HRMS: m/z calcd for [C₁₅H₁₄N₂O₂ ⁺]: 254.1055; found [M⁺]: 254.1050.
42 5-Methyl-2-phenyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-d]pyrimidine (2c) Сolorless crystals, 1.26 g, 40%, mp 190–192°С (2-PrOH). ¹H NMR (500 MHz, CDCl₃): δ = 2.01 (s, 3 H, 5-CH3), 3.09 (d, J = 17.4 Hz, 1 H, H-12a), 3.65 (dd, J = 17.5, 5.6 Hz, 1 H, H-12b), 5.44 (d, J = 5.5 Hz, 1 H, H-11), 6.77 (dd, J = 8.2, 1.1 Hz, 1 H, Н-7), 6.89 (td, J = 7.5, 1.2 Hz, 1 H, H-9), 7.04 (dd, J = 7.7, 1.6 Hz, 1 H, H-10), 7.11 (td, J = 8.5, 1.6 Hz, 1 H, H-8), 7.43–7.46 (m, 3 H, H-3′, 4′, 5′ Ph), 8.34–8.40 (m, 2 H, H-2′, 6′ Ph), 8.82 (s, 1 H, H-4) ppm. ¹³C NMR (126 MHz, CDCl₃): δ = 164.2, 161.8, 154.6, 150.6, 137.1, 130.9, 129.0, 128.5 (2 С), 128.2 (2 С), 127.8, 125.6, 122.6, 121.3, 117.0, 95.6, 69.3 (CH), 39.1 (CH2), 25.7 (CH₃) ppm. MS (EI): m/z (Irel, %) = [M⁺] 316.16 (100), 315.16 (23), 273.10 (45), 170.07 (22), 104.07 (16), 43.04 (28). HRMS: m/z calcd for [C₂₀H₁₆N₂O₂ ⁺]: 316.1212; found [M⁺]: 316.1214.
43 2-Methoxy-5-methyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-d]pyrimidine (2d) Сolorless crystals, 1.32 g, 49%, mp 125–127 °С (hexane). ¹H NMR (81 MHz, CDCl₃): δ = 1.95 (s, 3 H, 5-CH₃), 2.91 (d, J = 17.8 Hz, 1 H, H-12a), 3.54 (dd, J = 17.6, 5.5 Hz, 1 H, H-12b), 3.94 (s, 3 H, ОCH₃), 5.36 (d, J = 4.9 Hz, 1 H, H-11), 6.60–7.20 (m, 4 H, Н-7, 8, 9, 10), 8.54 (s, 1 H, Н-4) ppm. ¹³C NMR (20 MHz, CDCl₃): δ = 164.9, 164.4, 156.8, 150.6, 129.0, 125.6, 124.0, 122.6, 121.3, 117.0, 95.6, 69.1 (CH), 54.9 (OCH₃), 39.1 (CH₂), 25.9 (CH₃) ppm. MS (EI): m/z (Irel, %) = [M⁺] 269.50 (100), 256.09 (32), 254.71 (84), 252.89 (62), 226.87 (57), 212.04 (23), 176.93 (15), 110.08 (13), 51.05 (14), 43.05 (32). HRMS: m/z calcd for [C₁₅H₁₄N₂O₃ ⁺]: 270.1004; found [M⁺]: 270.1005.
44 5-Methyl-11,12-dihydro-5H-5,11-epoxybenzo[7,8]oxocino[4,3-d]pyrimidin-2-amine (2e) Сolorless crystals, 0.25 g, 10%, mp 186–188 °С (2-PrOH). ¹H NMR (81 MHz, CDCl₃): δ = 1.92 (s, 3 H, 5-CH₃), 2.75 (d, J = 17.3 Hz, 1H, H-12a), 3.43 (dd, J = 17.4, 5.5 Hz, 1 H, H-12b), 5.21 (br s, 2 H, NH₂), 5.33 (d, J = 5.6 Hz, 1 H, H-11), 6.60–7.21 (m, 4 H, H-7, 8, 9, 10), 8.33 (s, 1 H, H-4) ppm. ¹³C NMR (20 MHz, CDCl₃): δ = 163.0, 162.5, 156.1, 150.9, 129.0, 125.7, 122.9, 121.2, 120.7, 117.1, 96.0, 69.2 (CH), 39.0 (CH₂), 26.0 (CH₃) ppm. MS (EI): m/z (Irel, %) = [M⁺]: 255.07 (100), 238.07 (46), 238.07 (46), 212.05 (67), 95.04 (25), 65.06 (24), 51.03 (23), 43.03 (84). HRMS: m/z calcd for [C₁₄H₁₃N₃O₂ ⁺]: 255.1008; found [M⁺]: 255.1006.
45 X-ray Structural Study: Crystal Data for 2c Formula: C₂₀H₁₆N₂O₂, T = 296 K, M _r = 316.35 gmol^–1 , crystal size = 0.11 × 0.17 × 0.43 mm³, monoclinic, space group Cc, a = 16.7979(14) Å, b = 15.5100(11) Å, c = 25.2706(18) Å, β = 106.496(3)°, V = 6312.9(8) Å³ , Z = 16, ρ _calcd = 1.331 g cm^–3, μ = 0.087 mm^–1 , θ _max = 25.09°, 32245 reflections measured, 9755 unique, 6228 with I > 2σ(I), R _int = 0.049, R(I > 2σ(I)) = 0.0719, wR2 (all data) = 0.2220, GOF = 1.017, Δρ(min/max) = –0.29/0.49 eÅ³. CCDC 2292626 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures
46 Computational Details Computational studies were performed by DFT method^49, ⁵⁰ using Gaussian 16 software.⁵¹ B3LYP functional and 6-311++G(d,p) basis sets^[52,^53] with CPCM⁵⁴ approach to account the solvent effect (ethanol, dielectric constant ε = 24.852) were used for geometry optimization and Mulliken population analysis procedures. DFT B3LYP 6-311++G(d,p) has been considered as a suitable method for computational purposes due to many successful combined experimental and computational studies.^55–57 The structural formulas of the initial substances were used to obtain the starting geometries, which were then optimized without any constraints. After that frequency calculations were performed to ensure that the optimized structures are true energy minima. Optimized geometries of pyridines were used to analyze steric factors, as well as the Mulliken charges distribution on atoms. Basicity of pyrimidines was evaluated by the charge on nitrogen atom, CH acidity was estimated by the maximum charge on the hydrogen atom of the corresponding CH₃ group. The visualization of molecular structures and charge distribution was obtained using GaussView 6.⁵⁸.
47 X-ray Crystallographic Analysis of Compounds Crystal data collection and reduction were performed on a Bruker Kappa Apex II diffractometer with sealed-tube Mo Kα radiation using the APEX2⁵⁹ program. The absorption correction was made with the SADABS-2008/1⁶⁰ program. The crystal structure was solved using the SHELXT⁶¹ and it was refined using SHELXL⁶² programs. The H atoms were refined in riding model.
48 Synthesis of starting materials (compounds 1a–j) is given in the Supporting Information.
49 Becke AD. J. Chem. Phys. 1993; 98: 5648
50 Geerlings P, De Proft F, Langenaeker W. Chem. Rev. 2003; 103: 1793
51 Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA. Jr, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ö, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ. Gaussian 16, Revision B.01. Gaussian, Inc; Wallingford: 2016
52 McLean AD, Chandler GS. J. Chem. Phys. 1980; 72: 5639
53 Krishnan R, Binkley JS, Raymond JS, People JA. J. Chem. Phys. 1980; 72: 650
54 Tomasi J, Mennucci B, Cammi R. Chem. Rev. 2005; 105: 2999
55 Reed AE, Curtiss LA, Weinhold F. Chem. Rev. 1988; 88: 899
56 Kondage SS, Roemmele TL, Boeré RT. Synlett 2023; 34: 1113
57 Yavari I, Ravaghi P, Safaei M, Kayanian J. Synlett 2020; 31: 1691
58 Dennington R, Keith TA, Millam JM. GaussView, Version 6. Semichem, Inc; Shawnee Mission (KS, USA): 2016
59 APEX2, Bruker AXS Inc.; Madison: Wisconsin, USA
60 SADABS-2008/1, Bruker AXS Inc., Madison, Wisconsin, USA
61 Sheldrick GM. Acta Crystallogr., Sect. A: Found Adv. 2015; 71: 3
62 Sheldrick GM. Acta Crystallogr., Sect. C: Struct. Chem. 2015; 71: 3

Zusatzmaterial

Supporting Information (PDF)